Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2017 | Research

PDGFA/PDGFRα-regulated GOLM1 promotes human glioma progression through activation of AKT

Authors: Ran Xu, Jianxiong Ji, Xin Zhang, Mingzhi Han, Chao Zhang, Yangyang Xu, Yuzhen Wei, Shuai Wang, Bin Huang, Anjing Chen, Di Zhang, Qing Zhang, Wenjie Li, Zheng Jiang, Jian Wang, Xingang Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Abstract

Background

Golgi Membrane Protein 1 (GOLM1), a protein involved in the trafficking of proteins through the Golgi apparatus, has been shown to be oncogenic in a variety of human cancers. Here, we examined the role of GOLM1 in the development of human glioma.

Methods

qRT-PCR, immunohistochemistry, and western blot analysis were performed to evaluate GOLM1 levels in cell lines and a cohort of primary human glioma and non-neoplastic brain tissue samples. Glioma cell lines were modified with lentiviral constructs expressing short hairpin RNAs targeting GOLM1 or overexpressing the protein to assess function in proliferation, viability, and migration and invasion in vitro using EdU, CCK8, clone-forming, Transwell assays, 3D tumor spheroid invasion assay and in vivo in orthotopic implantations. Protein lysates were used to screen a membrane-based antibody array to identify kinases mediated by GOLM1. Specific inhibitors of PDGFRα (AG1296) and AKT (MK-2206) were used to examine the regulation of PDGFA/PDGFRα on GOLM1 and the underlying pathway respectively.

Results

qRT-PCR, immunohistochemistry and western blot analysis revealed GOLM1 expression to be elevated in glioma tissues and cell lines. Silencing of GOLM1 attenuated proliferation, migration, and invasion of U251, A172 and P3#GBM (primary glioma) cells, while overexpression of GOLM1 enhanced malignant behavior of U87MG cells. We further demonstrated that activation of AKT is the driving force of GOLM1-promoted glioma progression. The last finding of this research belongs to the regulation of PDGFA/PDGFRα on GOLM1, while GOLM1 was also a key element of PDGFA/PDGFRα-mediated activation of AKT, as well as the progression of glioma cells.

Conclusions

PDGFA/PDGFRα-regulated GOLM1 promotes glioma progression possibly through activation of a key signaling kinase, AKT. GOLM1 interference may therefore provide a novel therapeutic target and improve the efficacy of glioma treatment, particularly in the case of the proneural molecular subtype of human glioma.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMed

Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A. 2000;97:6242–4.CrossRefPubMedPubMedCentral

Bjerkvig R, Lundjohansen M, Edvardsen K. Tumor cell invasion and angiogenesis in the central nervous system. Curr Opin Oncol. 1997;9:223–9.CrossRefPubMed

Zhou X, Xie S, Wu S, et al. Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor. Neuro-Oncology. 2017;

Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000;249:53.CrossRefPubMed

Puri S, Bachert C, Fimmel CJ, et al. Cycling of early Golgi proteins via the cell surface and endosomes upon Lumenal pH disruption. Traffic. 2002;3:641–53.CrossRefPubMed

Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59:1687–93.CrossRefPubMed

Kristiansen G, Fritzsche FR, Wassermann K, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer. 2008;99:939–48.CrossRefPubMedPubMedCentral

Byrne AM, Bekiaris S, Duggan G, et al. Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion. Br J Cancer. 2015;113:1332–42.CrossRefPubMedPubMedCentral

10.

Liu G, Zhang Y, He F, et al. Expression of GOLPH2 is associated with the progression of and poor prognosis in gastric cancer. Oncol Rep. 2014;32:2077–85.CrossRefPubMed

11.

Donizy P, Kaczorowski M, Biecek P, et al. Golgi-related proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in cutaneous melanoma: patterns of expression and prognostic significance. Int J Mol Sci. 2016;17

12.

Ye QH, Zhu WW, Zhang JB, et al. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell. 2016;30:444–58.CrossRefPubMedPubMedCentral

13.

Kun-Wei, Shi-Yuan, Cheng. Platelet-derived growth factor receptor alpha in glioma: a bad seed. Chin J Cancer. 2011; 30: 590–602.

14.

Chaturvedi P, Gilkes DM, Wong CCL, et al. Hypoxia-inducible factor–dependent breastcancer–mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest. 2013;123:189–205.CrossRefPubMed

15.

Hu B, Wang Q, Wang Y A, et al. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell, 2016; 167: 1281–95. e18.

16.

Zhu C, Mustafa D, Zheng PP, et al. Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression. Neuro-Oncology. 2017;19:1–12.CrossRef

17.

Jue TR, Nozue K, Lester AJ, et al. Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. J Transl Med. 2017;15:61.CrossRefPubMedPubMedCentral

18.

Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311.CrossRefPubMed

19.

Yang N, Yan T, Zhu H, et al. A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma. J Transl Med. 2014;12:278.CrossRefPubMedPubMedCentral

20.

Buchanan PC, Klm B, Walcheck B, et al. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292:6339–51.CrossRefPubMed

21.

Lee HJ, Cao Y, Pham V, et al. Ras-MEK signaling mediates a critical Chk1-dependent DNA damage response in cancer cells. Mol Cancer Ther. 2017;16:694–704.CrossRefPubMed

22.

Schultz CR, Golembieski WA, King DA, et al. Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer. 2012;11:20.CrossRefPubMedPubMedCentral

23.

Ye S, Luo Q, Hao L, et al. Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer. 2014;13:65.CrossRef

24.

Gao G, Ke G, Ali S, et al. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nat Neurosci. 2017;20:1074–84.CrossRef

25.

Koul D, Shen R, Bergh S, et al. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006;5:637–44.CrossRefPubMed

26.

Iser IC, Pereira MB, Lenz G, et al. The epithelial - to - mesenchymal transition - like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev. 2016;37:271–313.CrossRefPubMed

27.

Wang X, Shi W, Shi H, et al. TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells. J Exp Clin Cancer Res. 2016;35:100.CrossRefPubMedPubMedCentral

28.

Xu Z, Yan Y, Xiao L, et al. Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway. PLoS One. 2017;12:e0175977.CrossRefPubMedPubMedCentral

29.

Narayan RS, Fedrigo CA, Brands E, et al. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. BMC Cancer. 2017;17:204.CrossRefPubMedPubMedCentral

30.

Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.CrossRefPubMedPubMedCentral

31.

Zhang L, Zhang W, Li Y, et al. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial - mesenchymal transition and invasion in mice and humans. Oncogene. 2016;35:5641–52.CrossRefPubMedPubMedCentral

32.

Sakakini N, Turchi L, Bergon A, et al. A positive feed-forward loop associating EGR1 and PDGFA promotes proliferation and self-renewal in glioblastoma stem cells. J Biol Chem. 2016;291:10684–99.CrossRefPubMedPubMedCentral

33.

Wamsley JJ, Gary C, Biktasova A, et al. Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner. Oncogene. 2017;6:e314.CrossRef

34.

Rajesh Y, Pal I, Banik P, et al. Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin. 2017;38:591–613.CrossRefPubMed

35.

Xu R, Han M, Xu Y, et al. Coiled-coil domain containing 109B is a HIF1α-regulated gene critical for progression of human gliomas. J Transl Med. 2017;15:165.CrossRefPubMedPubMedCentral

36.

Yu M, Xue Y, Zheng J, et al. Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway. Mol Cancer. 2017;16:110.CrossRefPubMedPubMedCentral

37.

Yang S, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017;16:124.CrossRefPubMedPubMedCentral

38.

Catalano M, D'Alessandro G, Lepore F, et al. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol Oncol. 2015;9:1612–25.CrossRefPubMedPubMedCentral

39.

Zhao P, Li Q, Shi Z, et al. GSK-3β regulates tumor growth and angiogenesis in human glioma cells. Oncotarget. 2015;6:31901–15.PubMedPubMedCentral

40.

Williams SP, Nowicki MO, Liu F, et al. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res. 2011;71:5374–80.CrossRefPubMedPubMedCentral

41.

Martinho O, Longatto-Filho A, Lambros MB, et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor a (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer. 2009;101:973–82.CrossRefPubMedPubMedCentral

42.

Ozawa T, Riester M, Cheng YK, et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014;26:288–300.CrossRefPubMedPubMedCentral

43.

Richardson WD, Pringle N, Mosley MJ, et al. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell. 1988;53:309–19.CrossRefPubMed

44.

Pietras K, Sjöblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3:439–43.CrossRefPubMed

45.

Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493–502.CrossRefPubMed

46.

Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42.CrossRefPubMed

Title: PDGFA/PDGFRα-regulated GOLM1 promotes human glioma progression through activation of AKT
Authors: Ran Xu
Jianxiong Ji
Xin Zhang
Mingzhi Han
Chao Zhang
Yangyang Xu
Yuzhen Wei
Shuai Wang
Bin Huang
Anjing Chen
Di Zhang
Qing Zhang
Wenjie Li
Zheng Jiang
Jian Wang
Xingang Li
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-017-0665-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

CDC42-interacting protein 4 promotes metastasis of nasopharyngeal carcinoma by mediating invadopodia formation and activating EGFR signaling

PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients

The α-melanocyte stimulating hormone/peroxisome proliferator activated receptor-γ pathway down-regulates proliferation in melanoma cell lines

Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2

Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer

ALX4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering Wnt/β-catenin pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer